跳至主要内容
临床试验/ISRCTN63231313
ISRCTN63231313进行中(未招募)3 期

Remote Ischaemic Conditioning After Stroke Trial (ReCAST- 3)

niversity of Nottingham0 个研究点目标入组 1,300 人开始时间: 2020年4月20日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
1,300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current participant inclusion criteria as of 20/12/2023:
  • 1. Hyperacute ischaemic stroke
  • 2. < 24h post stroke onset
  • 3. Primary intracerebral haemorrhage ruled out on baseline clinical neuroimaging
  • 4. NIHSS score of 5-25 at randomisation
  • 5. Aged 18 years or above
  • Previous participant inclusion criteria as of 29/04/2020 to 20/12/2023:
  • 1. Hyperacute ischaemic stroke
  • 2. < 6 h post stroke onset
  • 3. Primary intracerebral haemorrhage ruled out on baseline clinical neuroimaging
  • 4. NIHSS score of greater than 3 at randomisation
  • 5. Aged 18 years or above
  • Previous participant inclusion criteria:
  • 1. Hyperacute ischaemic stroke
  • 2. < 6 h post stroke onset
  • 3. Primary intracerebral haemorrhage ruled out on baseline clinical neuroimaging
  • 4. NIHSS score > 4 at randomisation
  • 5. Aged > 18 years

排除标准

  • Current participant exclusion criteria as of 20/12/2023:
  • 1. Pre-morbid dependency (modified Rankin Scale, mRS>3)
  • 2. Systolic BP =80 mmHg
  • 3. Spontaneous intracerebral haemorrhage
  • 4. Haemorrhagic transformation of infarction PH2 if known before randomisation (not excluded or withdrawn if occurs after randomisation)
  • 5. Dementia - if the patient had a pre-existing diagnosis
  • 6. Coma (GCS <8)
  • 7. Malignancy and significant co-morbidity (life expectancy <6 months)
  • 8. BM <3.0 mmol/L
  • 9. Seizure on presentation unless brain imaging identifies evidence of significant brain ischaemia
  • 10. Taking part in another interventional trial, unless co-enrolment has been approved by both Chief Investigators and Sponsors
  • 11. Known pregnancy
  • 12. Significant tissue injury of the upper limbs, which in the opinion of the investigator, will be exacerbated by RIC
  • 13. Expected repatriation to another hospital not participating in RECAST-3
  • Previous participant exclusion criteria as of 15/12/2021 to 20/12/2023:
  • 1. Pre-morbid dependency (modified Rankin Scale, mRS>3)
  • 2. Spontaneous intracerebral haemorrhage
  • 3. Haemorrhagic transformation of infarction PH2
  • 4. Dementia
  • 5. Coma (GCS <8)
  • 6. Malignancy and significant co-morbidity (life expectancy <6 months)
  • 7. BM <3.0 mmol/L
  • 8. Seizure on presentation unless brain imaging identifies evidence of significant brain ischaemia
  • 9. Taking part in another interventional trial, unless co-enrolment has been approved by both Chief Investigators and Sponsors
  • 10. Known pregnancy
  • Previous participant exclusion criteria as of 29/04/2020:
  • 1. Pre-morbid dependency (modified Rankin Scale, mRS> 3)
  • 2. Spontaneous intracerebral haemorrhage
  • 3. Dementia
  • 4. Coma (GCS < 8)
  • 5. Malignancy
  • 6. Significant co-morbidity (life expectancy < 6 months)
  • 7. BM < 3.0 mmol/L
  • 8. Seizure on presentation unless brain imaging identifies evidence of significant brain ischaemia
  • 9. Known pregnancy
  • Previous participant exclusion criteria:
  • 1. Pre-morbid dependency (modified Rankin Scale, mRS> 3)
  • 2. Spontaneous intracerebral haemorrhage
  • 3. Dementia
  • 4. Coma (GCS < 8)
  • 5. Malignancy
  • 6. Significant co-morbidity (life expectancy < 6 months)
  • 7. BM < 3.0 mmol/L
  • 8. Seizure on presentation unless brain imaging identifies evidence of significant brain ischaemia
  • 9. Long term (> 7 days) nitrate therapy
  • 10. Receiving treatment for diabetes
  • 11. Pregnancy

研究者

发起方
niversity of Nottingham

相似试验